OriGene to Acquire SDIX's Life Science Business Assets
ROCKVILLE, Md., April 8, 2013
ROCKVILLE, Md., April 8, 2013 /PRNewswire/ --OriGene Technologies, Inc., a
leading genome wide product company for research and diagnostic applications
with operations in the United States and China, announced that it has signed a
definitive agreement to acquire all the assets of the Life Science business of
SDIX™ (NASDAQ: SDIX), a leading provider of biotechnology-based products and
"We anticipate the combination of SDIX with OriGene will enhance our ability
to continue to develop the most comprehensive collection of high-quality
monoclonal antibodies for key applications both in research and diagnostics
fields. SDIX's over 20 years of antibody development and production expertise
will complement OriGene's existing high-throughput monoclonal antibody
capacity to develop the highest quality antibodies such as UltraMAB™," said
Wei-Wu He, Ph.D., OriGene's Chairman and Chief Executive Officer. OriGene
expects the acquisition of SDIX to:
oEnhance the capabilities of OriGene to provide the most comprehensive
immunization strategies for antibody development using full-length
mammalian produced protein and genetic immunization technologies to create
the highest quality monoclonal antibodies available
oExpand antibody and IVD reagent product and services capabilities to
create significant new commercial opportunities for our existing and new
customers including producing UltraMAB™ for future diagnostic uses
This transaction will uniquely position OriGene as one of the leaders in
antibody development and production to help our customers find the best
solutions for their antibody and assay needs. The acquisition is expected to
be completed during the second quarter of 2013, subject to the approval of
SDIX's shareholders and other customary closing conditions.
About OriGene Technologies
OriGene Technologies, Inc. develops, manufactures, and sells genome wide
research and diagnostic products worldwide. OriGene has developed an
extensive array of ultra-specific monoclonal antibodies called UltraMAB™ which
offers significant improvement over traditional antibodies in antibody
specificity. UltraMAB™ antibodies are validated by OriGene's proprietary high
density microarray technology for a wide variety of antibody applications.
For more information, visit www.origene.com.
SOURCE OriGene Technologies, Inc.
Press spacebar to pause and continue. Press esc to stop.